Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term immunogenicity of TdcP-IPV with or without concurrent hepatitis B vaccine in adolescents
2015-005196-24Phase 4
- Sponsor
- Sanofi
- Start
- Nov 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) and Hepatitis B vaccine in diphtheria, Tetanus, pertussis and 2 more (2 arms), sponsored by Sanofi. Primary endpoint: Seroprotection against diphtheria and tetanus antigens.
02
Drugs
diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)Hepatitis B vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitishepatitis B (HBV)
Beyond the preview
Go deeper on 2015-005196-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005196-24.